effect of buprenorphine patch(when placed on the skin) after uterus removal for few hours

efficacy of transdermal buprenorphine patch in postoperative period in hysterectomy patients

Status

Active, not recruiting

Phases

Phase 2Phase 3

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2020/10/028677

Enrollment

100

Registered

2020-10-28

Start date

Unknown

Completion date

Unknown

Last updated

2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: N711- Chronic inflammatory disease of uterus Health Condition 2: C55- Malignant neoplasm of uterus, partunspecified Health Condition 3: C55- Malignant neoplasm of uterus, partunspecified

Interventions

Intervention1: buprenorphine transdermal patch: NIL Control Intervention1: comparison of buprenorphine transdermal patch with placebo patch: to see the effect of both patches in postoperative pain for

Eligibility

Inclusion criteria

Inclusion criteria: female patients who have to undergo elective transabdominal hysterectomy

Exclusion criteria

Exclusion criteria: patient refusal, patients with skin allergies,patient on opioid treatment,patient who are not fit for subarachanoid block

Design outcomes

Primary

Measure	Time frame
time of first rescue analgesiaTimepoint: within 24 hours	—

Secondary

Measure	Time frame
total doses of rescue analgesia in 1st 24 hours of postoperative periodTimepoint: within 24 hours	—

Countries

India

Contacts

Public ContactNandini sood

IGMC Shimla

drrajeshkverma@gmail.com9805130100

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026